Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients

Detalhes bibliográficos
Autor(a) principal: Silva, Sandra Helena Kaznowski da
Data de Publicação: 2022
Outros Autores: Oliveira, Livia Costa de, Peres, Wilza Arantes Ferreira, Wiegert, Emanuelly Varea Maria, Motta, Rachel Souza Thompson, Silva, Naira Freire da, Lopes, Márcia Soares da Mota e Silva
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Research, Society and Development
Texto Completo: https://rsdjournal.org/index.php/rsd/article/view/31783
Resumo: Objectives: This study aimed to determine the prognostic value of the pretreatment inflammatory indexes neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, and platelet-lymphocyte ratio in breast cancer. Methods: A retrospective cohort of patients with breast cancer receiving treatment at a specialized cancer hospital were collected from 2016. Pretreatment complete blood cell counts were evaluated to assess inflammatory indexes. The outcome variable was 5-year overall survival. Kaplan-Meier curves, log-rank test, and Cox regression (hazard ratio; 95% confidence interval) were used. Results: A total of 312 women (mean age 51.9 years; histopathological grade II 61.6%; tumor stage III 50.0%) were included in the study. Of these, 169 (54.2%) died within 5 years, the majority of whom had neutrophil-lymphocyte ratio ≥ 2.5 (62.5%; p= 0.002), histopathological grades II and III (60.4%; p= 0.024), more advanced tumor stages (87.7%; p<0.001), and significantly lower overall survival. Neutrophil-lymphocyte ratio ≥ 2.5 (hazard ratio, 1.53; 95% CI, 1.11-2.11) was an independent prognostic factor for overall survival. In addition, histopathological grades II (hazard ratio, 3.53; 95% confidence interval, 1.29-9.68) and III stage (hazard ratio, 2.50; 95% confidence interval, 1.45-4.34) and stage IV (hazard ratio, 6.07; 95% confidence interval, 3.43-10.73) demonstrated predictive power. Conclusion: Pretreatment neutrophil-lymphocyte ratio was considered a useful predictor of overall survival in breast cancer.
id UNIFEI_d5e9e6d0e6ea3b6d55f450d97dbe9643
oai_identifier_str oai:ojs.pkp.sfu.ca:article/31783
network_acronym_str UNIFEI
network_name_str Research, Society and Development
repository_id_str
spelling Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients La relación neutrófilos-linfocitos previa al tratamiento tiene valor pronóstico en pacientes con cáncer de mamaA relação neutrófilo-linfócito pré-tratamento tem valor prognóstico em pacientes com câncer de mama Cáncer de mamaInflamaciónBiomarcadoresPronósticoSupervivencia.Breast cancerPrognosisInflammationBiomarkersSurvival.Câncer de mamaInflamaçãoBiomarcadoresPrognósticoSobrevida.Objectives: This study aimed to determine the prognostic value of the pretreatment inflammatory indexes neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, and platelet-lymphocyte ratio in breast cancer. Methods: A retrospective cohort of patients with breast cancer receiving treatment at a specialized cancer hospital were collected from 2016. Pretreatment complete blood cell counts were evaluated to assess inflammatory indexes. The outcome variable was 5-year overall survival. Kaplan-Meier curves, log-rank test, and Cox regression (hazard ratio; 95% confidence interval) were used. Results: A total of 312 women (mean age 51.9 years; histopathological grade II 61.6%; tumor stage III 50.0%) were included in the study. Of these, 169 (54.2%) died within 5 years, the majority of whom had neutrophil-lymphocyte ratio ≥ 2.5 (62.5%; p= 0.002), histopathological grades II and III (60.4%; p= 0.024), more advanced tumor stages (87.7%; p<0.001), and significantly lower overall survival. Neutrophil-lymphocyte ratio ≥ 2.5 (hazard ratio, 1.53; 95% CI, 1.11-2.11) was an independent prognostic factor for overall survival. In addition, histopathological grades II (hazard ratio, 3.53; 95% confidence interval, 1.29-9.68) and III stage (hazard ratio, 2.50; 95% confidence interval, 1.45-4.34) and stage IV (hazard ratio, 6.07; 95% confidence interval, 3.43-10.73) demonstrated predictive power. Conclusion: Pretreatment neutrophil-lymphocyte ratio was considered a useful predictor of overall survival in breast cancer.Objetivos: Este estudio tuvo como objetivo determinar el valor pronóstico de los índices inflamatorios previos al tratamiento, la relación neutrófilos-linfocitos, la relación linfocitos-monocitos y la relación plaquetas-linfocitos en el cáncer de mama. Métodos: Se recopiló una cohorte retrospectiva de pacientes con cáncer de mama que recibieron tratamiento en un hospital oncológico especializado a partir de 2016. Se evaluaron los hemogramas completos previos al tratamiento para evaluar los índices inflamatorios. La variable de resultado fue la supervivencia global a los 5 años. Se utilizaron curvas de Kaplan-Meier, log-rank test y regresión de Cox (hazard ratio; intervalo de confianza del 95%). Resultados: Se incluyeron en el estudio un total de 312 mujeres (edad media 51,9 años; grado histopatológico II 61,6%; estadio tumoral III 50,0%). De estos, 169 (54,2%) fallecieron dentro de los 5 años, la mayoría con cociente neutrófilo-linfocito ≥ 2,5 (62,5%; p= 0,002), grados histopatológicos II y III (60,4%; p= 0,024), tumor más avanzado (87,7%; p<0,001), y una supervivencia global significativamente menor. La relación neutrófilos-linfocitos ≥ 2,5 (cociente de riesgos instantáneos, 1,53; IC del 95 %, 1,11-2,11) fue un factor pronóstico independiente para la supervivencia global. Además, los grados histopatológicos II (razón de riesgo, 3,53; intervalo de confianza del 95 %, 1,29-9,68) y estadio III (razón de riesgo, 2,50; intervalo de confianza del 95 %, 1,45-4,34) y estadio IV (razón de riesgo, 6,07; 95 % intervalo de confianza, 3.43-10.73) demostró poder predictivo. Conclusión: la proporción de neutrófilos-linfocitos antes del tratamiento se consideró un predictor útil de la supervivencia global en el cáncer de mama.Objetivos: Este estudo teve como objetivo determinar o valor prognóstico dos índices inflamatórios pré-tratamento relação neutrófilo-linfócito, relação linfócito-monócito e relação plaqueta-linfócito no câncer de mama. Métodos: Uma coorte retrospectiva de pacientes com câncer de mama em tratamento em um hospital especializado em câncer foi coletada a partir de 2016. Hemogramas completos pré-tratamento foram avaliados para avaliar os índices inflamatórios. A variável de desfecho foi a sobrevida global em 5 anos. Curvas de Kaplan-Meier, teste de log-rank e regressão de Cox (hazard ratio; intervalo de confiança de 95%) foram usados. Resultados: Um total de 312 mulheres (idade média de 51,9 anos; grau histopatológico II 61,6%; estágio do tumor III 50,0%) foram incluídas no estudo. Destes, 169 (54,2%) morreram em 5 anos, a maioria com relação neutrófilo-linfócito ≥ 2,5 (62,5%; p= 0,002), graus histopatológicos II e III (60,4%; p= 0,024), tumores mais avançados (87,7%; p<0,001) e sobrevida global significativamente menor. Razão neutrófilos-linfócitos ≥ 2,5 (hazard ratio, 1,53; IC 95%, 1,11-2,11) foi um fator prognóstico independente para a sobrevida global. Além disso, os graus histopatológicos II (hazard ratio, 3,53; intervalo de confiança de 95%, 1,29-9,68) e estágio III (hazard ratio, 2,50; intervalo de confiança de 95%, 1,45-4,34) e estágio IV (hazard ratio, 6,07; 95% intervalo de confiança, 3,43-10,73) demonstrou poder preditivo. Conclusão: A relação neutrófilos-linfócitos pré-tratamento foi considerada um preditor útil de sobrevida global no câncer de mama.Research, Society and Development2022-07-06info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/3178310.33448/rsd-v11i9.31783Research, Society and Development; Vol. 11 No. 9; e17611931783Research, Society and Development; Vol. 11 Núm. 9; e17611931783Research, Society and Development; v. 11 n. 9; e176119317832525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIenghttps://rsdjournal.org/index.php/rsd/article/view/31783/27034Copyright (c) 2022 Sandra Helena Kaznowski da Silva; Livia Costa de Oliveira; Wilza Arantes Ferreira Peres; Emanuelly Varea Maria Wiegert; Rachel Souza Thompson Motta; Naira Freire da Silva; Márcia Soares da Mota e Silva Lopeshttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessSilva, Sandra Helena Kaznowski daOliveira, Livia Costa dePeres, Wilza Arantes Ferreira Wiegert, Emanuelly Varea Maria Motta, Rachel Souza ThompsonSilva, Naira Freire da Lopes, Márcia Soares da Mota e Silva 2022-07-21T12:36:16Zoai:ojs.pkp.sfu.ca:article/31783Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:48:00.695778Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false
dc.title.none.fl_str_mv Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients
La relación neutrófilos-linfocitos previa al tratamiento tiene valor pronóstico en pacientes con cáncer de mama
A relação neutrófilo-linfócito pré-tratamento tem valor prognóstico em pacientes com câncer de mama
title Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients
spellingShingle Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients
Silva, Sandra Helena Kaznowski da
Cáncer de mama
Inflamación
Biomarcadores
Pronóstico
Supervivencia.
Breast cancer
Prognosis
Inflammation
Biomarkers
Survival.
Câncer de mama
Inflamação
Biomarcadores
Prognóstico
Sobrevida.
title_short Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients
title_full Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients
title_fullStr Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients
title_full_unstemmed Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients
title_sort Pretreatment neutrophil-lymphocyte ratio has prognosis value in breast cancer patients
author Silva, Sandra Helena Kaznowski da
author_facet Silva, Sandra Helena Kaznowski da
Oliveira, Livia Costa de
Peres, Wilza Arantes Ferreira
Wiegert, Emanuelly Varea Maria
Motta, Rachel Souza Thompson
Silva, Naira Freire da
Lopes, Márcia Soares da Mota e Silva
author_role author
author2 Oliveira, Livia Costa de
Peres, Wilza Arantes Ferreira
Wiegert, Emanuelly Varea Maria
Motta, Rachel Souza Thompson
Silva, Naira Freire da
Lopes, Márcia Soares da Mota e Silva
author2_role author
author
author
author
author
author
dc.contributor.author.fl_str_mv Silva, Sandra Helena Kaznowski da
Oliveira, Livia Costa de
Peres, Wilza Arantes Ferreira
Wiegert, Emanuelly Varea Maria
Motta, Rachel Souza Thompson
Silva, Naira Freire da
Lopes, Márcia Soares da Mota e Silva
dc.subject.por.fl_str_mv Cáncer de mama
Inflamación
Biomarcadores
Pronóstico
Supervivencia.
Breast cancer
Prognosis
Inflammation
Biomarkers
Survival.
Câncer de mama
Inflamação
Biomarcadores
Prognóstico
Sobrevida.
topic Cáncer de mama
Inflamación
Biomarcadores
Pronóstico
Supervivencia.
Breast cancer
Prognosis
Inflammation
Biomarkers
Survival.
Câncer de mama
Inflamação
Biomarcadores
Prognóstico
Sobrevida.
description Objectives: This study aimed to determine the prognostic value of the pretreatment inflammatory indexes neutrophil-lymphocyte ratio, lymphocyte-monocyte ratio, and platelet-lymphocyte ratio in breast cancer. Methods: A retrospective cohort of patients with breast cancer receiving treatment at a specialized cancer hospital were collected from 2016. Pretreatment complete blood cell counts were evaluated to assess inflammatory indexes. The outcome variable was 5-year overall survival. Kaplan-Meier curves, log-rank test, and Cox regression (hazard ratio; 95% confidence interval) were used. Results: A total of 312 women (mean age 51.9 years; histopathological grade II 61.6%; tumor stage III 50.0%) were included in the study. Of these, 169 (54.2%) died within 5 years, the majority of whom had neutrophil-lymphocyte ratio ≥ 2.5 (62.5%; p= 0.002), histopathological grades II and III (60.4%; p= 0.024), more advanced tumor stages (87.7%; p<0.001), and significantly lower overall survival. Neutrophil-lymphocyte ratio ≥ 2.5 (hazard ratio, 1.53; 95% CI, 1.11-2.11) was an independent prognostic factor for overall survival. In addition, histopathological grades II (hazard ratio, 3.53; 95% confidence interval, 1.29-9.68) and III stage (hazard ratio, 2.50; 95% confidence interval, 1.45-4.34) and stage IV (hazard ratio, 6.07; 95% confidence interval, 3.43-10.73) demonstrated predictive power. Conclusion: Pretreatment neutrophil-lymphocyte ratio was considered a useful predictor of overall survival in breast cancer.
publishDate 2022
dc.date.none.fl_str_mv 2022-07-06
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/31783
10.33448/rsd-v11i9.31783
url https://rsdjournal.org/index.php/rsd/article/view/31783
identifier_str_mv 10.33448/rsd-v11i9.31783
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv https://rsdjournal.org/index.php/rsd/article/view/31783/27034
dc.rights.driver.fl_str_mv https://creativecommons.org/licenses/by/4.0
info:eu-repo/semantics/openAccess
rights_invalid_str_mv https://creativecommons.org/licenses/by/4.0
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Research, Society and Development
publisher.none.fl_str_mv Research, Society and Development
dc.source.none.fl_str_mv Research, Society and Development; Vol. 11 No. 9; e17611931783
Research, Society and Development; Vol. 11 Núm. 9; e17611931783
Research, Society and Development; v. 11 n. 9; e17611931783
2525-3409
reponame:Research, Society and Development
instname:Universidade Federal de Itajubá (UNIFEI)
instacron:UNIFEI
instname_str Universidade Federal de Itajubá (UNIFEI)
instacron_str UNIFEI
institution UNIFEI
reponame_str Research, Society and Development
collection Research, Society and Development
repository.name.fl_str_mv Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)
repository.mail.fl_str_mv rsd.articles@gmail.com
_version_ 1797052812624920576

Registros relacionados